# An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

> **NCT01607346** · PHASE4 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 10 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** ezogabine/retigabine

## Key facts

- **NCT ID:** NCT01607346
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03-27
- **Primary completion:** 2016-11-16
- **Final completion:** 2016-11-16
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01607346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01607346, "An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01607346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*